|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.08.26 - 20:01
|
AI Jitters Return as Markets Await Jobs Data | Open Interest 8/6/2026 (Bloomberg)
|
|
|
Get a jump start on the US trading day with Dani Burger on "Bloomberg Open Interest." Fresh AI weakness keeps investors on edge amid US-Iran talks and ahead of tomorrow's jobs report. Billions worth of SpaceX shares become eligible for trading following the company's post-earnings plunge. And AI investor Leopold Aschenbrenner returns to the investing game with a $400 million bet. Plus: the CEOs of Krispy Kreme, Smashburger, Roivant, and Lincoln International -- covering everything from food to biotech to M&A. (Source: Bloomberg)...
|
|
|
06.08.26 - 17:42
|
Roivant Expects FDA to Approve First Major Drug (Bloomberg)
|
|
|
Roivant Chief Executive Officer Matt Gline expects the FDA to approve the launch of a drug used to fight a debilitating skin disease. He says the drug should be on the market by September. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)...
|
|
|
|
|
|
|
23.07.26 - 22:09
|
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 (GlobeNewswire EN)
|
|
|
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Roivant Sciences Ltd. (ROIV), Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
